Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: A c-Fos and electrophysiological study

Brain

Volumn 119, Issue 1, 1996, Pages 249-256

  Hoskin, Karen L ^a   Kaube, Holger ^b   Goadsby, Peter J ^a,c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b Department of Neurology ^*  (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Acute treatment; Ergotamine; Headache; Migraine; Trigeminal nucleus

Indexed keywords

DIHYDROERGOTAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CAT; DRUG MECHANISM; GENE EXPRESSION; INTRAVENOUS DRUG ADMINISTRATION; MIGRAINE; NERVE STIMULATION; NOCICEPTION; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; SUPERIOR SAGITTAL SINUS; TRIGEMINAL NUCLEUS;

ANIMALS; CATS; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR CIRCULATION; DIHYDROERGOTAMINE; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; NEURAL PATHWAYS; PROTO-ONCOGENE PROTEINS C-FOS; SPINAL CORD; TRIGEMINAL NERVE; TRIGEMINAL NUCLEI; VASOCONSTRICTOR AGENTS;

EID: 0029979663     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/119.1.249     Document Type: Article

References (33)

1. Ala-Hurula V, Myllyla VV, Arvela P, Karki NT, Hokkanen E. Systemic availability of ergotamine tartrate after three successive doses and during continuous medication. Eur J Clin Pharmacol 1979;16: 355-60.
2. Berman AL. The brain stem of the cat. A cytoarchitectonic atlas with stereotaxic co-ordinates. Madison: University of Wisconsin Press, 1968.
3. Buzzi MG, Carter WB, Shimizu T, Heath H 3d, Moskowitz MA. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 1991; 30: 1193-200.
4. Dahlof C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J, et al. A multicentre, double-blind, placebo-controlled, doseranging study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. In: Rose, FC, editor. New advances in headache research: 4. London: Smith-Gordon, 1994: 17-18.
5. Eadie MJ. Ergotamine pharmacokinetics in man: an editorial. Cephalalgia 1983; 3: 135-8.
6. Goadsby PJ. Diagnosis and optimum treatment of migraine. CNS Drugs 1994; 1: 245-53.
7. Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 1994; 34: 394-9.
8. 3H]-dihydroergotamine binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 1991; 29: 91-4.
9. Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 1991; 114: 1001-11.
10. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183-7.
11. Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache 1991a; 31: 365-71.
12. Goadsby PJ, Zagami AS, Donnan GA, Symington G, Anthony M, Bladin PF, Lance JW. Oral sumatriptan in acutre migraine. Lancet 1991b; 338: 782-3.
13. Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Res Publ Assoc Res Nerv Ment Dis 1966; 18: 638-69.
14. 1b, binding sites in rat brain membranes: evidence for guanine nucleotide regulation of agonist affinity states. J Pharmacol Exp Ther 1987; 243: 989-1001.
15. Hammond DL, Presley R, Gogas KR, Basbaum AI. Morphine or U-50, 488 suppresses Fos protein-like immunoreactivity in the spinal cord and nucleus tractus solitarii evoked by a noxious visceral stimulus in the rat. J Comp Neurol 1992; 315: 244-53.
16. Hovdal H, Syversen GB, Rosenthaler J. Ergotamine in plasma and CSF after i.m. and rectal administration in humans. Cephalalgia 1982; 2: 145-50.
17. Hoyer D, Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites. Brain Res 1986; 376: 85-96.
18. Humphrey PPA, Feniuk W, Marriott AS, Tanner RJN, Jackson MR, Tucker ML. Preclinical studies on the anti-migraine drug, sumatriptan. [Review]. Eur Neurol 1991; 31: 282-90.
19. Kanto J, Allonen H, Koski K, Koulu M, Lammintausta R, Mantyla R, et al. Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. Int J Clin Pharmacol Ther Toxicol 1981; 19: 127-30.
20. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993a; 109: 788-92.
21. Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ. Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Res 1993b; 629: 95-102.
22. Lambert GA, Lowy AJ, Boers PM, Angus-Leppan H, Zagami AS. The spinal cord processing of input from the superior sagittal sinus: pathway and modulation by ergot alkaloids. Brain Res 1992; 597: 321-30.
23. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. [Review]. Trends Pharmacol Sci 1992; 13: 307-11.
24. Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. [Review]. Ann Rev Med 1993; 44: 145-54.
25. Peroutka SJ. Antimigraine drug interactions with serotonin receptor subtypes in human brain. Ann Neurol 1988; 23: 500-4.
26. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986; 36: 995-7.
27. Raskin NH. Headache. 2nd ed. New York: Churchill Livingstone, 1988.
28. Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache 1987; 27: 416-20.
29. Ray BS, Wolff HG. Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch Surg 1940; 41: 813-56.
30. Rexed B. A cytoarchitectonic atlas of the spinal cord in the cat. J Comp Neurol 1954; 100: 297-379.
31. Siegel S. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill, 1956.
32. Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316-21.
33. Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990; 16: 69-75.